Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance

Advanced Drug Delivery Reviews

Volumn 60, Issue 12, 2008, Pages 1421-1434

  Thurber, Greg M ^a   Schmidt, Michael M ^a   Wittrup, K Dane ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Affinity; Antibodies; Binding site barrier; Cellular trafficking; Drug distribution; Immunotherapy; Mathematical modeling; Pharmacokinetics; Tumor targeting

Indexed keywords

ANTIBODIES; TUMORS;

CANCER IMAGING; ELSEVIER (CO); EXPERIMENTAL APPROACHES; HETEROGENEOUS DISTRIBUTIONS; LARGE REGIONS; RESISTANT CELLS; TUMOR PENETRATION; TUMOR TISSUES;

STABILIZERS (AGENTS);

ANTIGEN; IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIGEN SPECIFICITY; CANCER THERAPY; DIFFUSION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; IMMUNOTHERAPY; INTERNALIZATION; INTRACELLULAR TRANSPORT; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MAXIMUM TOLERATED DOSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; ANTIGENS; BIOLOGICAL TRANSPORT; CAPILLARY PERMEABILITY; DIFFUSION; ENDOCYTOSIS; HUMANS; METABOLIC CLEARANCE RATE; MODELS, THEORETICAL; NEOPLASM METASTASIS; NEOPLASMS; PERMEABILITY;

EID: 46849103828     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.04.012     Document Type: Review

References (162)

1. Weinstein J., Eger R., Covell D., Black C., Mulshine J., Carrasquillo J., Larson S., and Keenan A. The pharmacology of monoclonal antibodies. Ann. N.Y. Acad. Sci. 507 (1987) 199-210
2. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumours. Nat. Rev., Cancer 6 8 (2006) 583-592
3. Baxter L.T., and Jain R.K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res. 37 1 (1989) 77-104
4. Baxter L.T., and Jain R.K. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc. Res. 41 1 (1991) 5-23
5. Fujimori K., Covell D., Fletcher J., and Weinstein J. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. 31 (1990) 1191-1198
6. Graff C., and Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63 (2003) 1288-1296
7. Rippley R.K., and Stokes C.L. Effects of cellular pharmacology on drug distribution in tissues. Biophys J 69 3 (1995) 825-839
8. Wenning L.A., and Murphy R.M. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol. Bioeng. 62 5 (1999) 562-575
9. Swartz M.A. The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 50 1-2 (2001) 3-20
10. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1 (1999) 241-263
11. Pluen A., Boucher Y., Ramanujan S., McKee T.D., Gohongi T., di Tomaso E., Brown E.B., Izumi Y., Campbell R.B., Berk D.A., and Jain R.K. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. U. S. A. 98 8 (2001) 4628-4633
12. Deen W.M. Hindered transport of large molecules in liquid-filled pores. Aiche J. 33 9 (1987) 1409
13. Berk D., Yuan F., Leunig M., and Jain R.K. Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 1785-1790
14. Brown E., Boucher Y., Nasser S., and Jain R.K. Measurement of macromolecular diffusion coefficients in human tumors. Microvasc. Res. 67 (2004) 231-236
15. Davies Cde L., Berk D.A., Pluen A., and Jain R.K. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer 86 10 (2002) 1639-1644
16. Nugent L.J., and Jain R.K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res. 44 1 (1984) 238-244
17. Clauss M.A., and Jain R.K. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 50 12 (1990) 3487-3492
18. Crank J. The Mathematics of Diffusion. 2 ed. (1975), Clarendon Press, Oxford 414 pp.
19. Baish J., Gazit Y., Berk D., Nozue M., Baxter L., and Jain R.K. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc. Res. 51 (1996) 327-346
20. Fidler I.J., Yano S., Zhang R.D., Fujimaki T., and Bucana C.D. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 3 1 (2002) 53-57
21. Lyng H., Haraldseth O., and Rofstad E.K. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn. Reson. Med. 43 6 (2000) 828-836
22. Worthylake R., Opresko L.K., and Wiley H.S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem. 274 13 (1999) 8865-8874
23. Krol A., Maresca J., Dewhirst M.W., and Yuan F. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. Cancer Res. 59 16 (1999) 4136-4141
24. Bjornaes I., and Rofstad E.K. Transvascular and interstitial transport of a 19 kDa linear molecule in human melanoma xenografts measured by contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 14 5 (2001) 608-616
25. Green E. Biology of the Laboratory Mouse (1966), Dover Publications, New York
26. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93 11 (2004) 2645-2668
27. Milenic D.E., Yokota T., Filpula D.R., Finkelman M.A., Dodd S.W., Wood J.F., Whitlow M., Snoy P., and Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51 23 Pt 1 (1991) 6363-6371
28. Williams L.E., Wu A.M., Yazaki P.J., Liu A., Raubitschek A.A., Shively J.E., and Wong J.Y. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother. Radiopharm. 16 1 (2001) 25-35
29. Ghetie V., and Ward E.S. Transcytosis and catabolism of antibody. Immunol. Res. 25 2 (2002) 97-113
30. Garg A., and Balthasar J.P. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J. Pharmacokinet. Pharmacodyn. (2007)
31. Ferl G.Z., Wu A.M., and DiStefano III J.J. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann. Biomed. Eng. 33 11 (2005) 1640-1652
32. Holt L.J., Herring C., Jespers L.S., Woolven B.P., and Tomlinson I.M. Domain antibodies: proteins for therapy. Trends Biotechnol. 21 11 (2003) 484-490
33. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 9 (2005) 1126-1136
34. Deen, W.M., M.J. Lazzara, and B.D. Myers, Structural determinants of glomerular permeability. 2001. 281(4): F579-F596.
35. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., and King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17 8 (1999) 780-783
36. Yang K., Basu A., Wang M., Chintala R., Hsieh M.C., Liu S., Hua J., Zhang Z., Zhou J., Li M., Phyu H., Petti G., Mendez M., Janjua H., Peng P., Longley C., Borowski V., Mehlig M., and Filpula D. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 16 10 (2003) 761-770
37. Nguyen A., Reyes II A.E., Zhang M., McDonald P., Wong W.L., Damico L.A., and Dennis M.S. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng. Des. Sel. 19 7 (2006) 291-297
38. Muller D., Karle A., Meissburger B., Hofig I., Stork R., and Kontermann R.E. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem. 282 17 (2007) 12650-12660
39. Hu S., Shively L., Raubitschek A., Sherman M., Williams L.E., Wong J.Y., Shively J.E., and Wu A.M. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56 13 (1996) 3055-3061
40. Willuda J., Kubetzko S., Waibel R., Schubiger P.A., Zangemeister-Wittke U., and Pluckthun A. Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J. Biol. Chem. 276 17 (2001) 14385-14392
41. Levy G. Pharmacologic target-mediated drug disposition. Clin. Pharmacol. Ther. 56 3 (1994) 248-252
42. Mager D.E., and Jusko W.J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28 6 (2001) 507-532
43. Mager D.E. Target-mediated drug disposition and dynamics. Biochem. Pharmacol. 72 1 (2006) 1-10
44. Lammerts van Bueren J.J., Bleeker W.K., Bogh H.O., Houtkamp M., Schuurman J., van de Winkel J.G., and Parren P.W. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 66 15 (2006) 7630-7638
45. Ng C.M., Stefanich E., Anand B.S., Fielder P.J., and Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm. Res. 23 1 (2006) 95-103
46. Ng C.M., Joshi A., Dedrick R.L., Garovoy M.R., and Bauer R.J. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm. Res. 22 7 (2005) 1088-1100
47. Liu H., Rajasekaran A.K., Moy P., Xia Y., Kim S., Navarro V., Rahmati R., and Bander N.H. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 58 18 (1998) 4055-4060
48. Bryan J.N., Jia F., Mohsin H., Sivaguru G., Miller W.H., Anderson C.J., Henry C.J., and Lewis M.R. Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nucl. Med. Biol. 32 8 (2005) 851-858
49. Matzku S., Brocker E.B., Bruggen J., Dippold W.G., and Tilgen W. Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res. 46 8 (1986) 3848-3854
50. Kyriakos R.J., Shih L.B., Ong G.L., Patel K., Goldenberg D.M., and Mattes M.J. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res. 52 4 (1992) 835-842
51. Austin C., Maziere A., Pisacane P., van Dijk S., Eigenbrot C., Sliwkowski M., Klumperman J., and Scheller R. Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin. Mol. Biol. Cell 15 (2004) 5268-5282
52. Yao Z., Garmestani K., Wong K.J., Park L.S., Dadachova E., Yordanov A., Waldmann T.A., Eckelman W.C., Paik C.H., and Carrasquillo J.A. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J. Nucl. Med. 42 10 (2001) 1538-1544
53. van Schaijk F.G., Broekema M., Oosterwijk E., van Eerd J.E., McBride B.J., Goldenberg D.M., Corstens F.H., and Boerman O.C. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J. Nucl. Med. 46 6 (2005) 1016-1022
54. Michel R.B., Ochakovskaya R., and Mattes M.J. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels. Clin. Cancer Res. 8 8 (2002) 2632-2639
55. Mattes M.J., Griffiths G., Diril H., Goldenberg D., Ong G., and Shih L. Processing of Antibody-Radioisotope Conjugates after Binding to the Surface of Tumor Cells. Cancer 73 (1994) 787-793
56. Press O.W., Shan D., HowellClark J., Eary J., Appelbaum F.R., Matthews D., King D.J., Haines A.M.R., Hamann P., Hinman L., Shochat D., and Bernstein I.D. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56 9 (1996) 2123-2129
57. Ferl, G.Z., V. Kenanova, A.M. Wu, and J.J. DiStefano, A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. 2006. 5(6): 1550-1558.
58. Thurber G.M., Zajic S.C., and Wittrup K.D. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J. Nucl. Med. 48 6 (2007) 995-999
59. Romond, E.H., E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer, N.E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P.A. Kaufman, S.M. Swain, T.M. Pisansky, L. Fehrenbacher, L.A. Kutteh, V.G. Vogel, D.W. Visscher, G. Yothers, R.B. Jenkins, A.M. Brown, S.R. Dakhil, E.P. Mamounas, W.L. Lingle, P.M. Klein, J.N. Ingle, and N. Wolmark, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. 2005. 353(16): 1673-1684.
60. Baxter L., and Jain R.K. Transport of fluid and macromolecules in tumors 1. Role of interstitial pressure and convection. Microvasc. Res. 37 (1989) 77-104
61. Dreher M.R., Liu W.G., Michelich C.R., Dewhirst M.W., Yuan F., and Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Nat. Cancer Inst. 98 5 (2006) 335-344
62. Gerlowski L., and Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31 (1986) 288-305
63. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D., Torchilin V., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
64. Weis, S.M. and D.A. Cheresh, Pathophysiological consequences of VEGF-induced vascular permeability. 2005. 437(7058): 497-504.
65. Rippe B., and Haraldsson B. Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiol. Scand. 131 (1987) 411-428
66. Blanch H.W., and Clark D.S. Biochemical Engineering (1997), CRC Press 702 pp.
67. Varner J.D. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT). IEE Proc. Syst. Biol. 152 4 (2005) 291-302
68. Baxter L., Zhu H., Mackensen D., and Jain R.K. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 54 (1994) 1517-1528
69. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., and Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89 3 (1998) 307-314
70. Adams G., Schier R., McCall A., Simmons H., Horak E., Alpaugh K., Marks J., and Weiner L. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61 (2001) 4750-4755
71. Kievit E., Pinedo H.M., Schluper H.M., Haisma H.J., and Boven E. Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Br. J. Cancer 73 4 (1996) 457-464
72. Blumenthal R.D., Fand I., Sharkey R.M., Boerman O.C., Kashi R., and Goldenberg D.M. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol. Immunother. 33 6 (1991) 351-358
73. Thurber, G., M. Schmidt, and K.D. Wittrup, Poor Antibody Penetration into Tumors: Systemic and Endocytic Clearance Critically Limit Transport. TRENDS in Pharmacological Sciences, 29 (2) (2008) 57-61.
74. Schier R., McCall A., Adams G.P., Marshall K.W., Merritt H., Yim M., Crawford R.S., Weiner L.M., Marks C., and Marks J.D. Isolation of picomolar affinity Anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263 4 (1996) 551-567
75. Schoeberl B., Eichler-Jonsson C., Gilles E.D., and Muller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. 20 4 (2002) 370-375
76. Tang Y., Lou J., Alpaugh R.K., Robinson M.K., Marks J.D., and Weiner L.M. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J. Immunol. 179 5 (2007) 2815-2823
77. Zhou, H.N., G. Randers-Pehrson, C.A. Waldren, D. Vannais, E.J. Hall, and T.K. Hei, Induction of a bystander mutagenic effect of alpha particles in mammalian cells. 2000. 97(5): 2099-2104.
78. Couturier, O., S. Supiot, M. Degraef-Mougin, A. Faivre-Chauvet, T. Carlier, J.F. Chatal, F. Davodeau, and M. Cherel, Cancer radioimmunotherapy with alpha-emitting nuclides. 2005. 32(5): 601-614.
79. Adams G.P., Schier R., McCall A.M., Crawford R.S., Wolf E.J., Weiner L.M., and Marks J.D. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77 9 (1998) 1405-1412
80. Zuckier L.S., Berkowitz E.Z., Sattenberg R.J., Zhao Q.H., Deng H.F., and Scharff M.D. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res. 60 24 (2000) 7008-7013
81. Adams G.P., Schier R., Marshall K., Wolf E.J., McCall A.M., Marks J.D., and Weiner L.M. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58 3 (1998) 485-490
82. Ahlstrom H., Christofferson R., and Lorelius L. Vascularization of the continuous human colonic cancer cell line LS 174 T deposited subcutaneously in nude rats. APMIS 96 (1988) 701-710
83. Dewhirst, M.W., H. Kimura, S.W.E. Rehmus, R.D. Braun, D. Papahadjopoulos, K. Hong, and T.W. Secomb, Microvascular studies on the origins of perfusion-limited hypoxia. 1996. 74: S247-S251.
84. Boucher Y., and Jain R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 52 (1992) 5110-5114
85. Chaplin D.J., Olive P.L., and Durand R.E. Intermittent blood-flow in a murine tumor - radiobiological effects. Cancer Res. 47 2 (1987) 597-601
86. Eskey C.J., Koretsky A.P., Domach M.M., and Jain R.K. H-2-nuclear magnetic-resonance-imaging of tumor blood-flow - spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. Cancer Res. 52 21 (1992) 6010-6019
87. Honess, D.J., Y. Kitamoto, M.R. Rampling, and N.M. Bleehen, Nicotinamide and pentoxifylline increase human leucocyte filterability: A possible mechanism for reduction of acute hypoxia. 1996. 74: S236-S240.
88. Hobbs S., Monsky W., Yuan F., Roberts W., Griffith L., Torchilin V., and Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4607-4612
89. Liu G., He J., Dou S., Gupta S., Rusckowski M., and Hnatowich D.J. Further investigations of morpholino pretargeting in mice - establishing quantitative relations in tumor. Eur. J. Nucl. Med. Mol. Imaging 32 9 (2005) 1115-1123
90. Sharkey R.M., Karacay H., Richel H., McBride W.J., Rossi E.A., Chang K., Yeldell D., Griffiths G.L., Hansen H.J., and Goldenberg D.M. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin. Cancer Res. 9 10 Pt 2 (2003) 3897S-3913S
91. Koppe M.J., Soede A.C., Pels W., Oyen W.J., Goldenberg D.M., Bleichrodt R.P., and Boerman O.C. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int. J. Cancer 106 6 (2003) 965-972
92. Kranenborg M.H., Boerman O.C., Oosterwijk-Wakka J.C., de Weijert M.C., Corstens F.H., and Oosterwijk E. Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma × anti-DTPA bispecific monoclonal antibodies. Int. J. Cancer 75 1 (1998) 74-80
93. Juweid, M., R. Neumann, C. Paik, M.J. Perezbacete, J. Sato, W. Vanosdol, J.N. Weinstein, Micropharmacology of Monoclonal-Antibodies in Solid Tumors - Direct Experimental-Evidence for a Binding-Site Barrier. 1992. 52(19): 5144-5153.
94. Fenwick J., Philpott G., and Connett J. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (MAb) 1A3: the influence of administered MAb dose on tumor uptake. Int. J. Cancer 44 (1989) 1017-1027
95. Haskin, J.A., D.J. Warner, and D.U. Blank, Acute renal failure after large doses of intravenous immune globulin. 1999. 33(7-8): 800-803.
96. Ratko T.A., Burnett D.A., Foulke G.E., Matuszewski K.A., and Sacher R.A. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University hospital consortium expert panel for off-label use of polyvalent intravenously administered immunoglobulin preparations. JAMA 273 23 (1995) 1865-1870
97. Behr T.M., Behe M., Stabin M.G., Wehrmann E., Apostolidis C., Molinet R., Strutz F., Fayyazi A., Wieland E., Gratz S., Koch L., Goldenberg D.M., and Becker W. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: Therapeutic efficacy and dose-limiting toxicity of Bi-213- versus Y-90-labeled CO17-1A Fab ' fragments in a human colonic cancer model. Cancer Res. 59 11 (1999) 2635-2643
98. Wu A.M., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23 9 (2005) 1137-1146
99. Norum, J., Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. 2006. 18(5): 532-537.
100. Frykholm G., Glimelius B., Richter S., and Carlsson J. Heterogeneity in antigenic expression and radiosensitivity in human colon-carcinoma cell-lines. In Vitro Cell. Dev. Biol. 27 12 (1991) 900-906
101. Liao S.K., Meranda C., Avner B.P., Romano T., Husseini S., Kimbro B., and Oldham R.K. Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies. Cancer Immunol. Immunother. 28 2 (1989) 77-86
102. Mothersill, C. and C. Seymour, Radiation-induced bystander and other non-targeted effects: Novel intervention points in cancer therapy? 2006. 6(5): 447-454.
103. Lustig H.J., and Bianco C. Antibody-mediated cell cytotoxicity in a defined system - regulation by antigen, antibody, and complement. J. Immunol. 116 1 (1976) 253-260
104. Epstein A.L., Chen F.M., and Taylor C.R. A novel method for the detection of necrotic lesions in human cancers. Cancer Res. 48 20 (1988) 5842-5848
105. Friedman L.M., Rinon A., Schechter B., Lyass L., Lavi S., Bacus S.S., Sela M., and Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 102 6 (2005) 1915-1920
106. Ballesta, A.M., R. Molina, X. Filella, J. Jo, and N. Gimenez, Carcinoembryonic Antigen in Staging and Follow-up of Patients with Solid Tumors. 1995. 16(1): 32-41.
107. Prinssen H.M., Molthoff C.F., Verheijen R.H., Broadhead T.J., Kenemans P., Roos J.C., Davies Q., van Hof A.C., Frier M., den Hollander W., Wilhelm A.J., Baker T.S., Sopwith M., Symonds E.M., and Perkins A.C. Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. Cancer Immunol. Immunother. 47 1 (1998) 39-46
108. Knox S.J., Goris M.L., Trisler K., Negrin R., Davis T., Liles T.M., Grillo-Lopez A., Chinn P., Varns C., Ning S.C., Fowler S., Deb N., Becker M., Marquez C., and Levy R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2 3 (1996) 457-470
109. Flynn A.A., Boxer G.M., Begent R.H., and Pedley R.B. Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer. Immunol. Immunother. 50 2 (2001) 77-81
110. Sharkey R.M., Motta-Hennessy C., Pawlyk D., Siegel J.A., and Goldenberg D.M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 50 8 (1990) 2330-2336
111. Begent R.H., Verhaar M.J., Chester K.A., Casey J.L., Green A.J., Napier M.P., Hope-Stone L.D., Cushen N., Keep P.A., Johnson C.J., Hawkins R.E., Hilson A.J., and Robson L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2 9 (1996) 979-984
112. Kubetzko S., Balic E., Waibel R., Zangemeister-Wittke U., and Pluckthun A. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J. Biol. Chem. 281 46 (2006) 35186-35201
113. Delgado C., Pedley R.B., Herraez A., Boden R., Boden J.A., Keep P.A., Chester K.A., Fisher D., Begent R.H., and Francis G.E. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br. J. Cancer 73 2 (1996) 175-182
114. Li L., Yazaki P.J., Anderson A.L., Crow D., Colcher D., Wu A.M., Williams L.E., Wong J.Y., Raubitschek A., and Shively J.E. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug. Chem. 17 1 (2006) 68-76
115. Dennis M.S., Jin H., Dugger D., Yang R., McFarland L., Ogasawara A., Williams S., Cole M.J., Ross S., and Schwall R. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 67 1 (2007) 254-261
116. Kenanova V., Olafsen T., Williams L.E., Ruel N.H., Longmate J., Yazaki P.J., Shively J.E., Colcher D., Raubitschek A.A., and Wu A.M. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res. 67 2 (2007) 718-726
117. Sutherland R., Buchegger F., Schreyer M., Vacca A., and Mach J.P. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res. 47 6 (1987) 1627-1633
118. Deckert P.M., Jungbluth A., Montalto N., Clark M.A., Finn R.D., Williams Jr. C., Richards E.C., Panageas K.S., Old L.J., and Welt S. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts. Int. J. Cancer 87 3 (2000) 382-390
119. Behr T.M., Memtsoudis S., Sharkey R.M., Blumenthal R.D., Dunn R.M., Gratz S., Wieland E., Nebendahl K., Schmidberger H., Goldenberg D.M., and Becker W. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int. J. Cancer 77 5 (1998) 787-795
120. DeNardo S.J., Richman C.M., Albrecht H., Burke P.A., Natarajan A., Yuan A., Gregg J.P., O'Donnel R.T., and DeNardo G.L. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted Radioimmunotherapy for metastatic prostate cancer. Clin. Cancer Res. 11 19 (2005) 7187S-7194S
121. Sundaresan G., Yazaki P.J., Shively J.E., Finn R.D., Larson S.M., Raubitschek A.A., Williams L.E., Chatziioannou A.F., Gambhir S.S., and Wu A.M. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 44 12 (2003) 1962-1969
122. Kenanova V., Olafsen T., Crow D.M., Sundaresan G., Subbarayan M., Carter N.H., Ikle D.N., Yazaki P.J., Chatziioannou A.F., Gambhir S.S., Williams L.E., Shively J.E., Colcher D., Raubitschek A.A., and Wu A.M. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 65 2 (2005) 622-631
123. Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J., and Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24 5 (2006) 823-834
124. Bagshawe K.D., Sharma S.K., and Begent R.H. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin. Biol. Ther. 4 11 (2004) 1777-1789
125. van Schaijk F.G., Oosterwijk E., Soede A.C., Broekema M., Frielink C., McBride W.J., Goldenberg D.M., Corstens F.H.M., and Boerman O.C. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody. Clin. Cancer Res. 11 19 (2005) 7130S-7136S
126. Sung C., and Vanosdol W.W. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J. Nucl. Med. 36 5 (1995) 867-876
127. Lin Y., Pagel J.M., Axworthy D., Pantelias A., Hedin N., and Press O.W. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res. 66 7 (2006) 3884-3892
128. Medzihradszky K.F., Spencer D.I., Sharma S.K., Bhatia J., Pedley R.B., Read D.A., Begent R.H., and Chester K.A. Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 14 1 (2004) 27-37
129. S. Melkko, C. Halin, L. Borsi, L. Zardi, and D. Neri, An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. 2002. 54(5): 1485-1490.
130. Dellian M., Yuan F., Trubetskoy V.S., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer 82 9 (2000) 1513-1518
131. Y. Tabata, T. Kawai, Y. Murakami, and Y. Ikada, Electric charge influence of dextran derivatives on their tumor accumulation after intravenous injection. 1997. 4(3): 213-221.
132. Onda M., Kreitman R.J., Vasmatzis G., Lee B., and Pastan I. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J. Immunol. 163 11 (1999) 6072-6077
133. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 4587 (1983) 983-985
134. Roberts W.G., and Palade G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108 Pt 6 (1995) 2369-2379
135. Rosenstein M., Ettinghausen S.E., and Rosenberg S.A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol. 137 5 (1986) 1735-1742
136. Khawli L.A., Hu P., and Epstein A.L. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin. Cancer Res. 11 8 (2005) 3084-3093
137. LeBerthon B., Khawli L.A., Alauddin M., Miller G.K., Charak B.S., Mazumder A., and Epstein A.L. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res. 51 10 (1991) 2694-2698
138. Halin C., Niesner U., Villani M.E., Zardi L., and Neri D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int. J. Cancer 102 2 (2002) 109-116
139. Galaup A., Cazes A., Le Jan S., Philippe J., Connault E., Le Coz E., Mekid H., Mir L.M., Opolon P., Corvol P., Monnot C., and Germain S. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc. Natl. Acad. Sci. U. S. A. 103 49 (2006) 18721-18726
140. Criscuoli M.L., Nguyen M., and Eliceiri B.P. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 105 4 (2005) 1508-1514
141. D. Burke, M.M. Davies, J. Zweit, M.A. Flower, R.J. Ott, M.J. Dworkin, C. Glover, V.R. McCready, P. Carnochan, and T.G. Allen-Mersh, Continuous angiotensin II infusion increases tumour: normal blood flow ratio in colo-rectal liver metastases. 2001. 85(11): 1640-1645.
142. Kinuya, S., K. Yokoyama, A. Kawashima, T. Hiramatsu, S. Konishi, N. Shuke, N. Watanabe, T. Takayama, T. Michigishi, and N. Tonami, Pharmacologic intervention with angiotensin II and kinase inhibitor enhanced efficacy of radioimmunotherapy in human colon cancer xenografts. 2000. 41(7): 1244-+.
143. P.A. Netti, L.M. Hamberg, J.W. Babich, D. Kierstead, W. Graham, G.J. Hunter, G.L. Wolf, A. Fischman, Y. Boucher, and R.K. Jain, Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules. 1999. 96(6): 3137-3142.
144. Netti P.A., Baxter L.T., Boucher Y., Skalak R., and Jain R.K. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res. 55 22 (1995) 5451-5458
145. Znati C.A., Rosenstein M., Boucher Y., Epperly M.W., Bloomer W.D., and Jain R.K. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res. 56 5 (1996) 964-968
146. Baranowska-Kortylewicz J., Abe M., Pietras K., Kortylewicz Z.P., Kurizaki T., Nearman J., Paulsson J., Mosley R.L., Enke C.A., and Ostman A. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 65 17 (2005) 7824-7831
147. Pietras K., Stumm M., Hubert M., Buchdunger E., Rubin K., Heldin C.H., McSheehy P., Wartmann M., and Ostman A. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9 10 Pt 1 (2003) 3779-3787
148. Lee I., Boucher Y., and Jain R.K. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res. 52 11 (1992) 3237-3240
149. T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D.D. Hu-Lowe, D.R. Shalinsky, G. Thurston, G.D. Yancopoulos, and D.M. McDonald, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. 2004. 165(1): 35-52.
150. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 5706 (2005) 58-62
151. Tong R., Boucher Y., Kozin S., Winkler F., Hicklin D., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
152. Turetschek K., Preda A., Novikov V., Brasch R., Weinmann H., Wunderbaldinger P., and Roberts T. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J. Magn. Reson. Imaging 20 (2004) 138-144
153. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., and Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. Proc. Natl. Acad. Sci. U. S. A. 93 25 (1996) 14765-14770
154. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 23 (2004) 2335-2342
155. Jain R.K., Tong R.T., and Munn L.L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67 6 (2007) 2729-2735
156. Nakahara T., Norberg S.M., Shalinsky D.R., Hu-Lowe D.D., and McDonald D.M. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 66 3 (2006) 1434-1445
157. McIntosh D., Tan X., Oh P., and Schnitzer J. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sci. U. S. A. 99 4 (2002) 1996-2001
158. John T.A., Vogel S.M., Tiruppathi C., Malik A.B., and Minshall R.D. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am. J. Physiol. Lung Cell Mol. Physiol. 284 1 (2003) L187-L196
159. Tiruppathi C., Naqvi T., Wu Y., Vogel S.M., Minshall R.D., and Malik A.B. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 101 20 (2004) 7699-7704
160. Sparreboom A., Scripture C.D., Trieu V., Williams P.J., De T., Yang A., Beals B., Figg W.D., Hawkins M., and Desai N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 11 11 (2005) 4136-4143
161. Sands H., Jones P.L., Shah S.A., Palme D., Vessella R.L., and Gallagher B.M. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res. 48 1 (1988) 188-193
162. Ballangrud A.M., Yang W.H., Charlton D.E., McDevitt M.R., Hamacher K.A., Panageas K.S., Ma D.S., Bander N.H., Scheinberg D.A., and Sgouros G. Response of LNCaP spheroids after treatment with an alpha-particle emitter (Bi-213)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 61 5 (2001) 2008-2014